MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries

Rhea-AI Summary

MyoKardia, Inc. (Nasdaq: MYOK) announced the presentation of data from its Phase 2a study of danicamtiv, a treatment for chronic heart failure with reduced ejection fraction (HFrEF), at the European Society of Cardiology's HFA Discoveries event. Scheduled for June 19, 2020, the session includes insights on danicamtiv’s mechanism of action. A conference call on June 22, 2020, will discuss study results, accessible via phone and webcast. MyoKardia specializes in precision medicine for cardiovascular diseases, aiming to innovate therapies targeting cardiac muscle contraction.

Positive

• Presentation of Phase 2a study results at a reputable event.
• Danicamtiv shows potential in treating chronic heart failure with reduced ejection fraction.

Negative

• No specific financial metrics or significant business developments disclosed.

-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 --

BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv (formerly MYK-491) in patients with chronic heart failure with reduced ejection fraction (HFrEF) will be presented in a late-breaker session at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries (HFA Discoveries) event. Danicamtiv is MyoKardia’s lead activator candidate designed to increase the contractility of the heart (systolic function) with minimal or no effect on myocardial relaxation and compliance (diastolic function) by acting directly on the proteins in the heart muscle responsible for contraction.

Friday, June 19, 2020
Late-Breaking Science Session 6 - Pharmacotherapy
5:00 p.m. – 5:45 p.m. CEST (11:00 a.m. – 11:45 a.m. ET)
Oral Presentation: Phase 2a Study of Danicamtiv (MYK-491) in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
Presented by Adriaan Voors, M.D., Ph.D, University Medical Center Groningen, Groningen, Netherlands

HFA Discoveries will also publish data from nonclinical studies elucidating danicamtiv’s mechanism of activity in a presentation titled, “Danicamtiv (MYK-491) A Novel Small-Molecule Cardiac Activator: in vitro/in vivo Evidence for Overall Myocardial Inotropy,” by Carlos del Rio, PhD, FACC, MyoKardia Staff Scientist, Pharmacology. 

Conference Call and Webcast
MyoKardia management will host a conference call and webcast on Monday, June 22, 2020 beginning at 8:30 a.m. ET/5:30 a.m. PT to discuss the danicamtiv results. Investors and analysts may access the call by dialing +1 (844) 494-0193 (domestic) or (508) 637-5584 (international) and referencing the conference ID 4787504. A live webcast of the conference call will be available on the Investor section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast, and accompanying slides, will be available on the MyoKardia website for 90 days following the call.

About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by (1) understanding the biomechanical underpinnings of disease; (2) targeting the proteins that modulate a given condition; (3) identifying patient populations with shared disease characteristics; and (4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Contacts: 
Michelle Corral 
Corporate Communications & Investor Relations
MyoKardia, Inc.
650-351-4690

FAQ

What are the results of the Phase 2a study of danicamtiv by MyoKardia?

The results will be presented at the HFA Discoveries event on June 19, 2020, but specific outcomes were not disclosed in the press release.

When is the MyoKardia conference call regarding danicamtiv results?

The conference call is scheduled for June 22, 2020, at 8:30 a.m. ET.

What is the focus of MyoKardia's research?

MyoKardia focuses on developing targeted therapies for serious cardiovascular diseases, particularly through understanding cardiac muscle function.